All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Wiskott-Aldrich Syndrome Protein in Lymphomagenesis: Unraveling the Interplay Between Somatic Mutations, B-cell Receptor Signaling and Actin Dynamics

Public support

  • Provider

    Czech Science Foundation

  • Programme

  • Call for proposals

  • Main participants

    Univerzita Karlova / 1. lékařská fakulta

  • Contest type

    M2 - International cooperation

  • Contract ID

    26-22366K

Alternative language

  • Project name in Czech

    Wiskott-Aldrich Syndrome Protein in Lymphomagenesis: Unraveling the Interplay Between Somatic Mutations, B-cell Receptor Signaling and Actin Dynamics

  • Annotation in Czech

    Non-Hodgkin lymphomas (NHL) are the 5th to 9th most frequently diagnosed cancer word wide. The most frequent NHL type is diffuse large B-cell lymphoma (DLBCL) which has specifically defined genetic subtypes. One of them, the so called EZB DLBCL, is affected by somatic mutations of genes coding for proteins involved in the homeostasis of germinal center B cells (EZH2, GNA12, GNA13, S1PR2, ARHGEF1, RHOA). Based on the literature and preliminary data, we believe that these alterations affect the cortical actin dynamics and related B-cell receptor (BCR) signaling via modulation of the Wiskott-Aldrich syndrome protein (WASp) function. We propose that this phenomenon represents a potential therapeutic target and that WASp has additional lymphoma important nuclear function. These associations were not investigated before, therefore, we believe that our studies will bring important new information related to critical aspects of lymphomagenesis, and molecular mechanisms in general, as well as new therapeutic targets for patients with hematological cancers and with autoimmune disorders.

Scientific branches

  • R&D category

    ZV - Basic research

  • OECD FORD - main branch

    30204 - Oncology

  • OECD FORD - secondary branch

  • OECD FORD - another secondary branch

  • CEP - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

    FD - Oncology and haematology

Solution timeline

  • Realization period - beginning

    Jan 1, 2026

  • Realization period - end

    Dec 31, 2028

  • Project status

    Z - Beginning multi-year project

  • Latest support payment

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP26-GA0-GF-R

  • Data delivery date

    May 23, 2026

Finance

  • Total approved costs

    11,292 thou. CZK

  • Public financial support

    11,292 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    0 thou. CZK